IMUX | Immunic, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.0000 - 1.1000
52 Week Range	0.9700 - 2.1100
Beta	1.89
Implied Volatility	167.20%
IV Rank	26.80%
Day's Volume	1,290,110
Average Volume	885,387
Shares Outstanding	90,079,000
Market Cap	90,079,000
Sector	Healthcare
Industry	Biotechnology
IPO Date	2014-04-17

Valuation
Profitability
Growth
Health
P/E Ratio	-0.81
Forward P/E Ratio	N/A
EPS	-1.23
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	85
Country	USA
Website	IMUX

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

IMUX's peers: BCRX, GBIO, KRON, ERAS, CCCC, EWTX, FHTX, STTK, GLUE, KYMR, NRIX, KZR, SPRB, EYEN

*Chart delayed

Analyzing fundamentals for IMUX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see IMUX Fundamentals page.

Watching at IMUX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on IMUX Technicals page.